{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:58:51Z","timestamp":1780639131171,"version":"3.54.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"19","license":[{"start":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T00:00:00Z","timestamp":1698364800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T00:00:00Z","timestamp":1698364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s00432-023-05459-7","type":"journal-article","created":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T16:02:36Z","timestamp":1698422556000},"page":"17671-17682","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Role and efficacy of capecitabine in the anthracycline-free regimen in breast cancer patients: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"149","author":[{"given":"Sisi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lufeng","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaren","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youquan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,27]]},"reference":[{"issue":"2","key":"5459_CR1","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1517\/13543776.2012.661413","volume":"22","author":"P \u00c1lvarez","year":"2012","unstructured":"\u00c1lvarez P, Marchal JA, Boulaiz H et al (2012) 5-Fluorouracil derivatives: a patent review. Expert Opin Ther Pat 22(2):107\u2013123. https:\/\/doi.org\/10.1517\/13543776.2012.661413","journal-title":"Expert Opin Ther Pat"},{"issue":"4","key":"5459_CR2","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3892\/or.2023.8612","volume":"50","author":"SM Alzahrani","year":"2023","unstructured":"Alzahrani SM, Al Doghaither HA, Al-Ghafari AB, Pushparaj PN (2023) 5-Fluorouracil and capecitabine therapies for the treatment of colorectal cancer (review). Oncol Rep 50(4):175. https:\/\/doi.org\/10.3892\/or.2023.8612","journal-title":"Oncol Rep"},{"issue":"2","key":"5459_CR3","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1093\/annonc\/mdn592","volume":"20","author":"C Andreetta","year":"2009","unstructured":"Andreetta C, Puppin C, Minisini A et al (2009) Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer. Ann Oncol 20(2):265\u2013271. https:\/\/doi.org\/10.1093\/annonc\/mdn592","journal-title":"Ann Oncol"},{"issue":"3\u20134","key":"5459_CR4","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1159\/000329066","volume":"80","author":"T Bachelot","year":"2011","unstructured":"Bachelot T, Bajard A, Ray-Coquard I et al (2011) Final results of ERASME-4: a randomized trial of first-line docetaxel plus either capecitabine or epirubicin for metastatic breast cancer. Oncology 80(3\u20134):262\u2013268. https:\/\/doi.org\/10.1159\/000329066","journal-title":"Oncology"},{"issue":"1","key":"5459_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10549-021-06280-x","volume":"188","author":"N Dempsey","year":"2021","unstructured":"Dempsey N, Rosenthal A, Dabas N et al (2021) Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies. Breast Cancer Res Treat 188(1):21\u201336. https:\/\/doi.org\/10.1007\/s10549-021-06280-x","journal-title":"Breast Cancer Res Treat"},{"issue":"9814","key":"5459_CR6","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/S0140-6736(11)61625-5","volume":"379","author":"R Peto","year":"2012","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG), Peto R, Davies C, Godwin J et al (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100, 000 women in 123 randomised trials. Lancet (london, England) 379(9814):432\u2013444. https:\/\/doi.org\/10.1016\/S0140-6736(11)61625-5","journal-title":"Lancet (london, England)"},{"key":"5459_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ejca.2022.11.028","volume":"181","author":"MC Etienne-Grimaldi","year":"2023","unstructured":"Etienne-Grimaldi MC, Pallet N, Boige V et al (2023) Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency. Eur J Cancer (oxford, England: 1990) 181:3\u201317. https:\/\/doi.org\/10.1016\/j.ejca.2022.11.028","journal-title":"Eur J Cancer (oxford, England: 1990)"},{"issue":"1","key":"5459_CR8","doi-asserted-by":"publisher","first-page":"68","DOI":"10.4067\/s0034-98872018000100068","volume":"146","author":"R Hameau","year":"2018","unstructured":"Hameau R, Gabrielli L, Garrido M et al (2018) Cardiotoxicidad inducida por tratamientos oncol\u00f3gicos. Fundamentos para la implementaci\u00f3n de equipos de Cardio-Oncolog\u00eda [Cardiotoxicity of anticancer therapies. Towards the implementation of cardio-oncology units]. Rev Med Chil 146(1):68\u201377. https:\/\/doi.org\/10.4067\/s0034-98872018000100068","journal-title":"Rev Med Chil"},{"issue":"1","key":"5459_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41698-017-0034-x","volume":"1","author":"X Han","year":"2017","unstructured":"Han X, Zhou Y, Liu W (2017) Precision cardio-oncology: understanding the cardiotoxicity of cancer therapy. NPJ Precision Oncol 1(1):31. https:\/\/doi.org\/10.1038\/s41698-017-0034-x","journal-title":"NPJ Precision Oncol"},{"issue":"1","key":"5459_CR10","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1007\/s10637-010-9555-7","volume":"30","author":"JH Jeong","year":"2012","unstructured":"Jeong JH, Jung SY, Park IH et al (2012) Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer. Invest New Drugs 30(1):408\u2013416. https:\/\/doi.org\/10.1007\/s10637-010-9555-7","journal-title":"Invest New Drugs"},{"issue":"5","key":"5459_CR11","first-page":"1223","volume":"14","author":"S Kamoshida","year":"2005","unstructured":"Kamoshida S, Shiogama K, Shimomura R et al (2005) Immunohistochemical demonstration of fluoropyrimidine-metabolizing enzymes in various types of cancer. Oncol Rep 14(5):1223\u20131230","journal-title":"Oncol Rep"},{"key":"5459_CR12","doi-asserted-by":"publisher","first-page":"9605439","DOI":"10.1155\/2022\/9605439","volume":"2022","author":"D Kashyap","year":"2022","unstructured":"Kashyap D, Pal D, Sharma R et al (2022) Global increase in breast cancer incidence: risk factors and preventive measures. Biomed Res Int 2022:9605439. https:\/\/doi.org\/10.1155\/2022\/9605439","journal-title":"Biomed Res Int"},{"issue":"4","key":"5459_CR13","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.jclinepi.2012.09.016","volume":"66","author":"SY Kim","year":"2013","unstructured":"Kim SY, Park JE, Lee YJ et al (2013) Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol 66(4):408\u2013414. https:\/\/doi.org\/10.1016\/j.jclinepi.2012.09.016","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"5459_CR14","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.2967\/jnumed.115.165811","volume":"57","author":"N Kobashi","year":"2016","unstructured":"Kobashi N, Matsumoto H, Zhao S et al (2016) The thymidine phosphorylase imaging agent 123I-IIMU predicts the efficacy of capecitabine. J Nuclear Med 57(8):1276\u20131281. https:\/\/doi.org\/10.2967\/jnumed.115.165811","journal-title":"J Nuclear Med"},{"issue":"2","key":"5459_CR15","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s00795-005-0282-7","volume":"38","author":"M Kobayashi","year":"2005","unstructured":"Kobayashi M, Sugimoto T, Okabayashi T et al (2005) Localization of thymidine phosphorylase in breast cancer tissue. Med Mol Morphol 38(2):112\u2013117. https:\/\/doi.org\/10.1007\/s00795-005-0282-7","journal-title":"Med Mol Morphol"},{"issue":"1","key":"5459_CR16","doi-asserted-by":"publisher","first-page":"64","DOI":"10.15420\/ecr.2017:17:2","volume":"13","author":"A Koutsoukis","year":"2018","unstructured":"Koutsoukis A, Ntalianis A, Repasos E et al (2018) Cardio-oncology: a focus on cardiotoxicity. Eur Cardiol 13(1):64\u201369. https:\/\/doi.org\/10.15420\/ecr.2017:17:2","journal-title":"Eur Cardiol"},{"key":"5459_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.939048","volume":"13","author":"Z Li","year":"2022","unstructured":"Li Z, Zheng J, Ji Z et al (2022) Addition of capecitabine to adjuvant chemotherapy may be the most effective strategy for patients with early-stage triple-negative breast cancer: a network meta-analysis of 9 randomized controlled trials. Front Endocrinol 13:939048. https:\/\/doi.org\/10.3389\/fendo.2022.939048","journal-title":"Front Endocrinol"},{"issue":"11","key":"5459_CR18","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1016\/j.bcp.2007.05.008","volume":"74","author":"S Liekens","year":"2007","unstructured":"Liekens S, Bronckaers A, P\u00e9rez-P\u00e9rez MJ, Balzarini J (2007) Targeting platelet-derived endothelial cell growth factor\/thymidine phosphorylase for cancer therapy. Biochem Pharmacol 74(11):1555\u20131567. https:\/\/doi.org\/10.1016\/j.bcp.2007.05.008","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"5459_CR19","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s10549-013-2589-8","volume":"139","author":"HJ L\u00fcck","year":"2013","unstructured":"L\u00fcck HJ, Du Bois A, Loibl S et al (2013) Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group. Breast Cancer Res Treat 139(3):779\u2013787. https:\/\/doi.org\/10.1007\/s10549-013-2589-8","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"5459_CR20","doi-asserted-by":"publisher","first-page":"e333","DOI":"10.1093\/ehjci\/jeac106","volume":"23","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS et al (2022) 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J Cardiovasc Imaging 23(10):e333\u2013e465. https:\/\/doi.org\/10.1093\/ehjci\/jeac106","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"5459_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2023.101205","volume":"93","author":"R Mattioli","year":"2023","unstructured":"Mattioli R, Ilari A, Colotti B et al (2023) Doxorubicin and other anthracyclines in cancers: activity, chemoresistance and its overcoming. Mol Aspects Med 93:101205. https:\/\/doi.org\/10.1016\/j.mam.2023.101205","journal-title":"Mol Aspects Med"},{"issue":"1","key":"5459_CR22","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1093\/annonc\/mdp498","volume":"21","author":"D Mavroudis","year":"2010","unstructured":"Mavroudis D, Papakotoulas P, Ardavanis A et al (2010) Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer. Ann Oncol 21(1):48\u201354. https:\/\/doi.org\/10.1093\/annonc\/mdp498","journal-title":"Ann Oncol"},{"issue":"8","key":"5459_CR23","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/s0959-8049(98)00058-6","volume":"34","author":"M Miwa","year":"1998","unstructured":"Miwa M, Ura M, Nishida M et al (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer (oxford, England: 1990) 34(8):1274\u20131281. https:\/\/doi.org\/10.1016\/s0959-8049(98)00058-6","journal-title":"Eur J Cancer (oxford, England: 1990)"},{"issue":"2","key":"5459_CR24","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3322\/caac.21759","volume":"73","author":"D Moris","year":"2023","unstructured":"Moris D, Palta M, Kim C et al (2023) Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin 73(2):198\u2013222. https:\/\/doi.org\/10.3322\/caac.21759","journal-title":"CA Cancer J Clin"},{"key":"5459_CR25","unstructured":"National Comprehensive Cancer Network. Breast cancer (version 6.2021). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf. Accessed 9 Sep 2021"},{"key":"5459_CR26","doi-asserted-by":"publisher","first-page":"1610722","DOI":"10.3389\/pore.2022.1610722","volume":"28","author":"A Paszt","year":"2022","unstructured":"Paszt A, Ottlakan A, Abraham S et al (2022) Clinical benefits of oral capecitabine over intravenous 5-fluorouracyl regimen in case of neoadjuvant chemoradiotherapy followed by surgery for locally advanced rectal cancer. Pathol Oncol Res POR 28:1610722. https:\/\/doi.org\/10.3389\/pore.2022.1610722","journal-title":"Pathol Oncol Res POR"},{"key":"5459_CR27","unstructured":"Pizzorno G, Diasio RB and Cheng YC: Pyrimidine analogs. In: Holland-Frei Cancer Medicine. 6th edition. BC Decker, 2003. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK13287\/"},{"issue":"4","key":"5459_CR28","doi-asserted-by":"publisher","first-page":"473","DOI":"10.3233\/CBM-181301","volume":"23","author":"X Qin","year":"2018","unstructured":"Qin X, Chang F, Wang Z, Jiang W (2018) Correlation of circulating pro-angiogenic miRNAs with cardiotoxicity induced by epirubicin\/cyclophosphamide followed by docetaxel in patients with breast cancer. Cancer Biomark Sect A Disease Mark 23(4):473\u2013484. https:\/\/doi.org\/10.3233\/CBM-181301","journal-title":"Cancer Biomark Sect A Disease Mark"},{"issue":"15","key":"5459_CR29","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1089\/ars.2020.8019","volume":"32","author":"V Sala","year":"2020","unstructured":"Sala V, Della Sala A, Hirsch E, Ghigo A et al (2020) Signaling pathways underlying anthracycline cardiotoxicity. Antioxid Redox Signal 32(15):1098\u20131114. https:\/\/doi.org\/10.1089\/ars.2020.8019","journal-title":"Antioxid Redox Signal"},{"key":"5459_CR30","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.phrs.2017.09.020","volume":"127","author":"M Savi","year":"2018","unstructured":"Savi M, Frati C, Cavalli S et al (2018) Imatinib mesylate-induced cardiomyopathy involves resident cardiac progenitors. Pharmacol Res 127:15\u201325. https:\/\/doi.org\/10.1016\/j.phrs.2017.09.020","journal-title":"Pharmacol Res"},{"issue":"3","key":"5459_CR31","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/annonc\/mdt588","volume":"25","author":"CH Smorenburg","year":"2014","unstructured":"Smorenburg CH, de Groot SM, van Leeuwen-Stok AE et al (2014) A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG. Ann Oncol 25(3):599\u2013605. https:\/\/doi.org\/10.1093\/annonc\/mdt588","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"5459_CR32","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.ejon.2004.06.005","volume":"8","author":"CN Sternberg","year":"2004","unstructured":"Sternberg CN, Reichardt P, Holland M (2004) Development of and clinical experience with capecitabine (Xeloda) in the treatment of solid tumours. Eur J Oncol Nurs 8(Suppl 1):S4\u2013S15. https:\/\/doi.org\/10.1016\/j.ejon.2004.06.005","journal-title":"Eur J Oncol Nurs"},{"issue":"13","key":"5459_CR33","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jama.2020.1707","volume":"323","author":"WD Tap","year":"2020","unstructured":"Tap WD, Wagner AJ, Sch\u00f6ffski P et al (2020) Effect of doxorubicin plus olaratumab vs doxorubicin plus placebo on survival in patients with advanced soft tissue sarcomas: the ANNOUNCE randomized clinical trial. JAMA 323(13):1266\u20131276. https:\/\/doi.org\/10.1001\/jama.2020.1707","journal-title":"JAMA"},{"issue":"1","key":"5459_CR34","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.clinthera.2005.01.005","volume":"27","author":"CM Walko","year":"2005","unstructured":"Walko CM, Lindley C (2005) Capecitabine: a review. Clin Ther 27(1):23\u201344. https:\/\/doi.org\/10.1016\/j.clinthera.2005.01.005","journal-title":"Clin Ther"},{"issue":"1","key":"5459_CR35","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1186\/1745-6215-14-391","volume":"14","author":"Y Wang","year":"2013","unstructured":"Wang Y, Zeng T (2013) Response to: practical methods for incorporating summary time-to-event data into meta-analysis. Trials 14(1):391. https:\/\/doi.org\/10.1186\/1745-6215-14-391","journal-title":"Trials"},{"issue":"1","key":"5459_CR36","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1001\/jama.2020.23370","volume":"325","author":"X Wang","year":"2021","unstructured":"Wang X, Wang SS, Huang H et al (2021) Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment: the SYSUCC-001 randomized clinical trial. JAMA 325(1):50\u201358. https:\/\/doi.org\/10.1001\/jama.2020.23370","journal-title":"JAMA"},{"key":"5459_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2023.102825","volume":"65","author":"B Wang","year":"2023","unstructured":"Wang B, Jin Y, Liu J et al (2023a) EP1 activation inhibits doxorubicin-cardiomyocyte ferroptosis via Nrf2. Redox Biol 65:102825. https:\/\/doi.org\/10.1016\/j.redox.2023.102825","journal-title":"Redox Biol"},{"key":"5459_CR38","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-023-03585-y","author":"Y Wang","year":"2023","unstructured":"Wang Y, Hu H, Yu L, Zeng S (2023b) Physiologically based pharmacokinetic modeling for prediction of 5-FU pharmacokinetics in cancer patients with hepatic impairment after 5-FU and capecitabine administration. Pharm Res. https:\/\/doi.org\/10.1007\/s11095-023-03585-y","journal-title":"Pharm Res"},{"issue":"9","key":"5459_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004421.pub3","volume":"9","author":"ML Willson","year":"2019","unstructured":"Willson ML, Burke L, Ferguson T et al (2019) Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev 9(9):CD004421. https:\/\/doi.org\/10.1002\/14651858.CD004421.pub3","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"5459_CR40","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1186\/s12885-022-10439-0","volume":"22","author":"H Yang","year":"2022","unstructured":"Yang H, Xu L, Guan S et al (2022) Neoadjuvant docetaxel and capecitabine (TX) versus docetaxel and epirubicin (TE) for locally advanced or early her2-negative breast cancer: an open-label, randomized, multi-center, phase II Trial. BMC Cancer 22(1):1357. https:\/\/doi.org\/10.1186\/s12885-022-10439-0","journal-title":"BMC Cancer"},{"issue":"1","key":"5459_CR41","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s12885-022-09326-5","volume":"22","author":"F Ye","year":"2022","unstructured":"Ye F, Bian L, Wen J et al (2022) Additional capecitabine use in early-stage triple negative breast cancer patients receiving standard chemotherapy: a new era? A meta-analysis of randomized controlled trials. BMC Cancer 22(1):261. https:\/\/doi.org\/10.1186\/s12885-022-09326-5","journal-title":"BMC Cancer"},{"key":"5459_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.771839","volume":"12","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Ma K, Li J et al (2021) The clinical value of chemotherapy combined with capecitabine in triple-negative breast cancer-a meta-analysis. Front Pharmacol 12:771839. https:\/\/doi.org\/10.3389\/fphar.2021.771839","journal-title":"Front Pharmacol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-05459-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-023-05459-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-05459-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T11:12:57Z","timestamp":1700305977000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-023-05459-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,27]]},"references-count":42,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["5459"],"URL":"https:\/\/doi.org\/10.1007\/s00432-023-05459-7","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,27]]},"assertion":[{"value":"1 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}